Search Results for "TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2 breast cancer"

TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metas...

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer

ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355

Trastuzumab Duocarmazine for HER2+ Locally Advanced or Metastatic Cancer

Breast cancer trial updates at ESMO 2021

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches

69. ESMO 2023 - Metastatic Breast Cancer

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Medical update: HER2-Positive and triple-positive metastatic breast cancer

Targeted Therapy for HER2 & HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

PREDICT+ underestimates survival of patients with HER2+ early breast cancer